News / Finance
WhisperfromWallStreet.com "Morning Gainers - " - Bob Evans Farms, Inc.,BOBE - Antigenics Inc.,AGEN - Angiotech Pharmaceuticals, Inc.,ANPI
Bob Evans Farms - Antigenics Inc - Angiotech Pharmaceuticals, Inc.
Bob Evans Farms, Inc.,BOBE
Bob Evans Farms, Inc. is a publicly traded restaurant and retail food products company listed on the NASDAQ exchange under the ticker symbol BOBE. The Company owns and operates full-service restaurants under the Bob Evans and Mimi’s Café brand names. Bob Evans family restaurants serve customers primarily in the Midwest, mid-Atlantic and Southeast regions of the United States, while Mimi’s Café casual restaurants operate primarily in California and other western states. The Company's food products segment also produces and distributes pork sausage and a variety of convenience food items under the Bob Evans and Owens brand names.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
Antigenics Inc.,AGEN
Drug stocks advanced in midday action Tuesday as shares of Antigenics Inc. rocketed for the second session, following the release of positive data earlier this week for its kidney cancer therapy Oncophage.
The Amex Pharmaceutical Index was up 0.6% at 259.89 and the Amex Biotechnology Index climbed 2% to 666.19.
The Dow Jones Industrial Average was up about 20 points at 8,738.
Shares of Antigenics motored up 60% to $1.40. The stocks climbed almost 20% on Monday.
Early Monday, Antigenics said an analysis of Oncophage data showed the product helped certain kidney-cancer patients live appreciably longer. Oncophage is currently approved only in Russia. The company has also filed for approval in the European Union.
---
Angiotech Pharmaceuticals, Inc.,ANPI
Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific Corporation has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberté(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberté Atom next month.
"The rapid adoption of the TAXUS Express Atom Stent has confirmed the need for this type of stenting option in the treatment of small-vessel coronary artery disease," said Mark Turco, M.D., F.A.C.C., F.S.C.A.I., Director of the Center for Cardiac and Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. "The TAXUS Liberté Atom Stent provides clear design and deliverability advantages. Additionally, in the TAXUS Atlas Small Vessel clinical trial, the TAXUS Liberté Atom Stent yielded a two-year target lesion revascularization rate that was 60 percent less than the TAXUS Express Atom Stent. I am pleased to be able to offer this option to my patients."
----
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
